American Journal of Pharmacology

Research Article
Published: 16 Aug, 2026

Individualized Dosing of Immune Checkpoint Inhibitors a Population Pharmacokinetic Model for Responder-Stratified Therapy

Domina P*

Department of Emergency, University Hospital Center Split, Croatia

Abstract

Immune Checkpoint Inhibitors (ICIs) have revolutionized oncology, yet their high cost, narrow therapeutic window, and substantial inter-individual pharmacokinetic variability limit optimal therapeutic outcomes. Recent evidence indicates that patients who respond to anti-PD-1 and anti-CTLA-4 therapy exhibit a marked, time-dependent reduction in drug clearance, leading to supratherapeutic exposure at fixed-dose regimens. This technical report presents a population pharmacokinetic model for individualized ICI dosing that integrates baseline covariates (body weight, serum albumin, biological sex) with dynamic clearance changes stratified by responder status. The model predicts that responders achieve steady-state clearance reductions of approximately 35% compared to 10% in non-responders, enabling dose reductions of up to 28% while maintaining target exposure. Simulations across a heterogeneous cohort demonstrate mean drug savings of 13.6%, with 42% of patients achieving >20% dose reduction. These findings support the integration of therapeutic drug monitoring, in silico pharmacokinetic modeling, and response-adaptive dosing into clinical practice to reduce toxicity burden and treatment costs without compromising efficacy.

Keywords: Immune checkpoint inhibitors; Pharmacokinetics; Individualized dosing; Population PK model; Therapeutic drug monitoring; Precision oncology

Introduction

Immune Checkpoint Inhibitors (ICIs) have dramatically improved outcomes across multiple malignancies by releasing inhibitory mechanisms that control T-cell-mediated immunity. Agents targeting Cytotoxic T-Lymphocyte-Associated Antigen 4 (CTLA-4), programmed cell Death Protein 1 (PD-1), and its ligand PD-L1 including ipilimumab, pembrolizumab, nivolumab, cemiplimab, atezolizumab, avelumab, and durvalumab have become cornerstone therapies in modern oncology [1,2].

Despite their clinical success, ICIs present significant challenges. Anti-CTLA-4 therapy is associated with dose-dependent Immune-Related Adverse Events (irAEs), including diarrhea with or without colitis, skin rash, hepatitis, endocrinopathies, and severe neurologic complications. Anti-PD-1/PD-L1 agents, while exhibiting lower irAE frequency, still cause grade ≥ 3 toxicity in approximately 10% of patients, frequently necessitating treatment discontinuation. Concurrently, the high cost of biologic immunotherapy imposes substantial economic burden on healthcare systems.

A critical yet underutilized observation is the considerable inter-individual Pharmacokinetic (PK) variability of ICIs. Population PK analyses have identified baseline Body Weight (BW), serum albumin, and biological sex as significant covariates affecting monoclonal antibody clearance and volume of distribution. Furthermore, emerging data suggest that therapeutic response itself modulates drug disposition: responders demonstrate a pronounced, progressive decrease in clearance over time compared to non-responders [3], resulting in supratherapeutic drug concentrations at tumor sites when fixed dosing is maintained.

This phenomenon where effective anti-tumor immunity creates a positive feedback loop by reducing antibody clearance provides a mechanistic rationale for response-adaptive dosing. Peer and colleagues have proposed that in silico PK modeling and clearance estimation could enable individualized dosing regimens, potentially reducing both adverse effects and cost burden while preserving efficacy. However, no operational mathematical framework has been published to

OPEN ACCESS

Correspondence:
Domina P, Department of Emergency, University Hospital Center Split, Croatia,
E-mail: domina.petric@gmail.com

Received Date: *03 Aug 2026*
Accepted Date: *11 Aug 2026*
Published Date: *16 Aug 2026*

Citation:
Domina P. Individualized Dosing of Immune Checkpoint Inhibitors a Population Pharmacokinetic Model for Responder-Stratified Therapy. Am J Pharmacol. 2026; 8(1): 1041.

translate these concepts into clinical dosing algorithms.

The present technical report addresses this gap by developing and validating a population pharmacokinetic model that: (i) quantifies baseline clearance from readily available patient covariates; (ii) projects time-dependent clearance changes based on responder versus non-responder status; and (iii) calculates individualized maintenance doses to maintain target exposure within the plateaued exposure-response window characteristic of PD-1/PD-L1 inhibitors.

Technical Report

Population pharmacokinetic framework

The model is structured as a two-compartment population PK framework with time-dependent clearance, parameterized using covariate effects identified in published population analyses of monoclonal antibody ICIs. Allometric scaling is applied to body weight, with serum albumin and sex as additional fixed-effect covariates.

Baseline clearance model

Baseline clearance (CLbase) is modeled as a power function of body weight with multiplicative covariate effects:

$$CLbase = \theta CL \times (BW / 70)^{by} \times (Alb / 4.0)^{\theta Alb} \times \theta sex$$

where θCL is the typical clearance for a 70 kg male with albumin 4.0 g/dL, BW is body weight (kg), Alb is serum albumin (g/dL), and θsex equals 1.0 for males and 0.85 for females [4,5]. The exponent θAlb is negative (-0.5), reflecting the inverse relationship between albumin and clearance (hypoalbuminemia increases clearance via reduced protein binding and increased capillary permeability) (Table 1).

Time-dependent clearance: responder *vs.* non-responder

The central innovation of this model is the incorporation of response status as a time-varying covariate on clearance. Clinical observations indicate that effective anti-tumor immunity reduces antibody clearance, likely via modulation of Fc-receptor-mediated recycling and inflammatory changes in the reticuloendothelial system. This is modeled as an exponential approach to a group-specific maximum reduction:

$$CL(t) = CLbase \times [1 - \beta group \times (1 - e^{(-kcl \times t)})]$$

where βgroup equals 0.35 for responders and 0.10 for non-responders, and kcl = 0.05 day^{-1}. At steady state ($t \to \infty$), the clearance ratio between responders and non-responders is:

$$CL_{responder}(\infty) / CL_{non\text{-}responder}(\infty) = (1 - 0.35) / (1 - 0.10) = 0.65 / 0.90 \approx 0.72$$

Thus, responders achieve a 28% lower clearance at steady state, enabling proportional dose reduction without sacrificing target exposure. The time constant (1/kcl = 20 days) implies that 95% of the clearance change occurs within approximately 60 days (9 weeks), consistent with the typical timing of first radiologic response assessment.

Volume of distribution

Central Volume of Distribution (Vd) is modeled with analogous allometric and sex covariates:

$$Vd = \theta V \times (BW / 70)^{\theta V, BW} \times \theta V, sex$$

While Vd does not directly enter the dosing equation for intravenous monoclonal antibodies (bioavailability F = 1.0), it determines the initial concentration following bolus administration and informs loading dose considerations.

Individualized dose equation

The maintenance dose required to achieve target trough concentration Ctarget at dosing interval τ is:

$$Dose_{individual}(t) = CL(t) \times Ctarget \times \tau / F$$

For intravenous monoclonal antibodies, F = 1.0. The target concentration is selected at the lower plateau of the exposure-response curve (25 mg/L), consistent with published data showing that PD-1/PD-L1 inhibitors exhibit saturated efficacy above threshold exposure. This conservative target ensures that dose reductions in responders do not compromise anti-tumor activity [6].

For anti-CTLA-4 agents, where irAEs are dose-dependent, an optional safety ceiling is applied:

$$Dose_{safe}(t) = \min(Dose_{individual}(t), Dose_{standard} \times \gamma tox)$$

where γtox is a patient-specific toxicity scaling factor (e.g., 0.80 for patients with pre-existing autoimmune disease).

Simulation methods

The model was implemented in Python 3.12 using object-oriented programming to ensure reproducibility and clinical utility [7]. Two simulation scenarios were conducted:

Scenario A – Patient Archetypes: Six clinically representative patient profiles were simulated at baseline (Week 0), Week 12, and Week 36 to illustrate covariate and response-status effects on dosing requirements.

Scenario B – Heterogeneous Cohort: A Monte Carlo simulation of 100 patients was performed with body weight ~ N (75, 15^2) kg, albumin ~ N (3.8, 0.4^2) g/dL, sex randomly assigned (50:50), and responder probability 0.40. Dose savings were calculated relative to the standard regimen (70 kg male, albumin 4.0 g/dL, non-responder baseline).

Result

The archetype analysis reveals several clinically important patterns (Table 2). First, responders achieve substantial dose reductions (up to 35% for standard-profile males, 51% for female responders) due to the combined effects of lower baseline clearance (sex, body weight) and the pronounced time-dependent clearance decline. Second, patients with hypoalbuminemia require dose increases of approximately 14% despite non-responder status, highlighting the critical importance of albumin monitoring to prevent subtherapeutic exposure. Third, high body weight responders paradoxically require lower absolute doses than low body weight non-responders, demonstrating that body weight alone is an insufficient dosing metric.

Cohort simulation results

The Monte Carlo cohort simulation yielded the following distribution of dose savings at Week 36: mean 13.6%, median 15.6%, interquartile range [-5.2%, 28.4%]. Notably, 42% of simulated patients achieved >20% dose reduction, while 29% required doses exceeding the standard regimen (primarily low-albumin, high-BW non-responders). The maximum observed dose reduction was 51% (small female responder with normal albumin), while the maximum required increase was 26% (large male non-responder

Table 1: Population pharmacokinetic parameter estimates.

Parameter	Symbol	Estimate	Source / Rationale
Typical clearance	θCL	0.25 L/day	Pembrolizumab / Nivolumab population PK
BW exponent on CL	θBW	0.75	Allometric scaling [3]
Albumin exponent	θAlb	−0.50	Inverse proportionality [1]
Male sex factor	θsex,M	1	Reference
Female sex factor	θsex,F	0.85	Lower clearance in females [1]
Typical volume	θV	4.0 L	Central compartment volume
BW exponent on V	θV, BW	0.8	Allometric scaling
NR max CL reduction	βNR	0.10 (10%)	Non-responder plateau
Responder max CL reduction	βR	0.35 (35%)	Responder plateau [1]
CL decline rate	kcl	0.05 day^{-1}	Time to 95% plateau: ~60 days
Target concentration	Ctarget	25 mg/L	Exposure-response plateau threshold
Dosing interval	τ	21 days	Standard q3-week regimen

Table 2: Individualized dose recommendations by patient archetype.

Patient Profile	Time (weeks)	CL (L/day)	Dose (mg)	Dose (mg/kg)	*vs* Standard (%)
Standard (70 kg M, Alb 4.0)	0	0.25	131.2	1.88	0
Standard (70 kg M, Alb 4.0)	36	0.225	118.1	1.69	−10.0
Responder (70 kg M, Alb 4.0)	0	0.25	131.2	1.88	0
Responder (70 kg M, Alb 4.0)	36	0.163	85.3	1.22	−35.0
Non-responder (70 kg M, Alb 4.0)	36	0.225	118.1	1.69	−10.0
Female Responder (60 kg, Alb 4.0)	36	0.123	64.6	1.08	−50.8
Low Albumin NR (70 kg, Alb 2.5)	36	0.285	149.4	2.13	13.8
High BW Responder (90 kg, Alb 4.0)	36	0.196	103	1.14	−21.5
Female NR (60 kg, Alb 3.5)	36	0.182	95.6	1.59	−27.1



Figure A1: Population pharmacokinetic simulation outputs. (A) Clearance trajectories; (B) Individualized dose curves; (C) Covariate effects; (D) Cohort savings distribution.

Appendix: Model Visualization

Figure A1 presents four simulation panels generated from the population PK model: **(A)** time-dependent clearance trajectories stratified by response status and sex; **(B)** corresponding individualized dose curves in mg/kg; **(C)** covariate effects of body weight and albumin on baseline dose requirements; and (D) distribution of dose savings across a simulated 100-patient cohort.

with hypoalbuminemia).

Figure 1 (see Appendix) illustrates the time-dependent clearance trajectories, individualized dose curves, covariate effects on baseline dosing, and the cohort savings distribution.

Discussion

Clinical interpretation of covariate effects

The model quantifies three clinically actionable covariate effects on checkpoint inhibitor clearance. Body weight exhibits the expected

positive allometric relationship (exponent 0.75), consistent with physiologic scaling of metabolic capacity and vascular volume. However, the magnitude of this effect is modest compared to the combined impact of albumin and sex. Serum albumin demonstrates a strong inverse relationship with clearance; each 1.0 g/dL decrease from the reference 4.0 g/dL increases clearance by approximately 41%. This has immediate clinical relevance: cancer patients frequently present with hypoalbuminemia due to malnutrition, hepatic dysfunction, or systemic inflammation, and failure to account for this covariate risks systematic underdosing in the most vulnerable patients [8].

The female sex factor (15% lower clearance) is consistent with published population PK analyses and likely reflects differences in body composition, hepatic enzyme expression, and immunoglobulin clearance pathways. When combined with the responder effect, female responders emerge as the subgroup with the greatest potential for dose de-escalation up to 51% in the simulated archetype. This finding warrants prospective validation, as female sex has also been associated with higher irAE incidence in some studies [9], suggesting that dose reduction in this population may yield dual benefits of cost savings and toxicity mitigation.

Responder-stratified dosing and the exposure-response plateau

The exposure-response relationship for PD-1/PD-L1 inhibitors is characterized by a plateau, wherein efficacy saturates above threshold concentrations but toxicity continues to increase with exposure. This pharmacologic feature is the theoretical foundation for responder dose reduction: once target occupancy is achieved, additional drug provides no incremental anti-tumor benefit while amplifying irAE risk. The model leverages the observation that responders naturally develop lower clearance (likely via immune-mediated modulation of antibody disposition), allowing dose reduction to offset this accumulation and restore exposure to the therapeutic plateau.

The timing of dose adaptation is critical. With a clearance decline half-life of approximately 14 days, 95% of the maximal reduction is achieved by 9 weeks. This aligns well with standard first-response assessment at 8-12 weeks (two to three cycles), suggesting that dose adaptation could be implemented at the first radiologic evaluation without requiring additional monitoring visits. For patients with early radiologic evidence of response, dose reduction at Cycle 4 (Week 9) would capture the majority of PK changes while minimizing unnecessary exposure.

Safety considerations and dose-dependent toxicity

Anti-CTLA-4-associated irAEs exhibit clear dose-dependency, with higher incidence and severity at elevated exposure levels. The model's optional safety ceiling (γtox) provides a mechanism to enforce conservative dosing in high-risk populations, including patients with pre-existing autoimmune disease, prior irAEs, or concurrent immunosuppressive therapy. For anti-PD-1/PD-L1 agents, where dose-toxicity relationships are less pronounced, the primary benefit of individualized dosing shifts from toxicity prevention to cost reduction and prevention of cumulative low-grade toxicities that impair quality of [10].

Importantly, the model does not advocate empiric dose reduction before response confirmation. Premature de-escalation in pseudo-progressors or patients with delayed responses could compromise outcomes. Therefore, response assessment must utilize validated criteria (RECIST 1.1 or iRECIST for immunotherapy) and, where available, Circulating Tumor DNA (ctDNA) dynamics to distinguish true responders from transient fluctuations.

Economic implications and healthcare sustainability

With annual checkpoint inhibitor costs exceeding $150,000 per patient in many jurisdictions, even modest dose reductions translate to substantial savings. The cohort simulation projects mean drug savings of 13.6%, with 42% of patients achieving >20% reduction. Extrapolated to a 500-patient cohort, this represents potential savings of approximately $10-15 million annually, depending on agent selection and regional pricing. These savings must be weighed against the costs of Therapeutic Drug Monitoring (TDM) and PK modeling infrastructure; however, TDM costs are marginal compared to biologic drug expenditure, and in silico modeling can be integrated into existing electronic health record systems with minimal incremental cost.

The model also supports reference pricing and value-based reimbursement frameworks by providing objective, patient-level exposure data to justify individualized dosing. As payers increasingly demand evidence of cost-effectiveness, PK-guided dosing offers a precision medicine rationale for departing from flat pricing while maintaining clinical outcomes.

Limitations and Future Directions

Several limitations must be acknowledged. First, the model parameters are derived from published population PK analyses and may not generalize across all ICI agents. Agent-specific calibration (e.g., pembrolizumab *vs.* nivolumab vs. atezolizumab) is required for clinical implementation, as Fc-domain modifications and target binding kinetics influence clearance pathways. Second, the responder clearance reduction factor (βR = 0.35) is based on aggregate literature estimates and requires prospective validation with serial PK sampling in clinical trials. Third, the model assumes first-order clearance decline kinetics; more complex models (e.g., Michaelis-Menten saturation, time-varying volume of distribution) may be needed for patients with extreme obesity [11], hepatic impairment, or concurrent nephrotoxic agents.

Fourth, the model does not incorporate immunogenicity (anti-drug antibodies), which can dramatically alter clearance in a minority of patients. Routine TDM would detect such outliers and trigger manual dose revision. Finally, the exposure-response plateau assumption, while supported by current literature, may not hold for all tumor types or combination regimens (e.g., ICI plus chemotherapy or anti-angiogenic therapy), necessitating tumor-specific model validation.

Conclusion

- This technical report presents an operational population pharmacokinetic model for individualized checkpoint inhibitor dosing that integrates baseline patient covariates (body weight, serum albumin, biological sex) with dynamic, response-stratified clearance changes. The key findings are:

- Responders exhibit approximately 35% clearance reduction at steady state compared to 10% in non-responders, enabling dose reductions of up to 28% while maintaining target exposure within the therapeutic plateau.

- Baseline covariates exert substantial independent effects: hypoalbuminemia increases clearance by ~41% per 1.0 g/dL decrease,

while female sex reduces clearance by 15%. Body weight alone is insufficient for accurate dosing.

- In a simulated heterogeneous cohort, mean drug savings of 13.6% were projected, with 42% of patients achieving >20% dose reduction. Maximum savings (51%) occurred in small female responders with normal albumin.

- The model supports clinical implementation at standard response assessment timepoints (8-12 weeks), with clearance changes reaching 95% of steady state by 9 weeks.

- Integration with therapeutic drug monitoring and in silico PK modeling platforms can reduce both irAE burden (particularly for anti-CTLA-4 agents) and healthcare costs without compromising anti-tumor efficacy.

- We conclude that precision dosing of immune checkpoint inhibitors is both pharmacologically justified and clinically feasible. Prospective clinical trials comparing model-guided dosing to standard body-weight-based regimens are warranted to validate these projections and establish implementation protocols.

References

1. Petric D. Important aspects of checkpoint inhibitors' pharmacokinetics. TMR Pharmacol Res. 2023;3(1):1.
2. Peer CJ, Goldstein DA, Goodell JC, Nguyen R, Figg WD, Ratain MJ. Opportunities for using in silico-based extended dosing regimens for monoclonal antibody immune checkpoint inhibitors. Br J Clin Pharmacol. 2020;86(9):1769-77.
3. Bajaj G, Suryawanshi S, Roy A, Gupta M. Evaluation of covariate effects on pharmacokinetics of monoclonal antibodies in oncology. Br J Clin Pharmacol. 2019;85(9):2045-58.
4. Li B, Chan HL, Chen PP. Immune Checkpoint Inhibitors: Basics and Challenges. Curr Med Chem. 2019;26(17):3009-25.
5. Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16(9):563-80.
6. Trinh S, Le A, Gowani S, La-Beck NM. Management of Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitor Therapy: A Minireview of Current Clinical Guidelines. Asia Pac J Oncol Nurs. 2019;6(2):154-60.
7. Buchbinder EI, Desai A. CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. Am J Clin Oncol. 2016;39(1):98-106.
8. Abril-Rodriguez G, Ribas A. SnapShot: Immune Checkpoint Inhibitors. Cancer Cell. 2017;31(6):848-848.e1.
9. Gronde TVD, Uyl-de Groot CA, Pieters T. Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks. PLoS One. 2017;12(8):e0182613.
10. Acosta A, Ciapponi A, Aaserud M, Vietto V, Austvoll-Dahlgren A, Kösters JP, et al. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies. Cochrane Database Syst Rev. 2014;2014(10):CD005979.
11. Likic R. Sustainability of costs of novel biologicals: Are we all heading for bankruptcy? Br J Clin Pharmacol. 2020;86(7):1233-4.